Every Form 4 that Keros Therapeutics, Inc. (KROS) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow KROS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full KROS filings page.
Keros Therapeutics, Inc. (KROS) reported that Annita Tanini, Corp. Controller & VP, Finance, sold 1,224 shares of common stock on 2026-08-18 at a weighted average price of $10.29 per share. The company states these were automatic "sell-to-cover" transactions to satisfy tax withholding on vested restricted stock units, and Ms. Tanini now holds 45,144 shares directly.
Keros Therapeutics, Inc. (KROS) reported that Chief Scientific Officer Lorena Raquel Lerner sold 3,568 shares of common stock on 2026-08-18 at a weighted average price of $10.29 per share, in automatic "sell-to-cover" transactions for tax withholding on vesting RSUs. Following these sales, she held 27,559 shares of common stock directly.
Keros Therapeutics, Inc. (KROS) reported a Form 4 for Chief Legal Officer Esther Cho. On 2026-08-18, she sold 4,485 shares of common stock at a weighted average price of $10.29 per share in automatic "sell-to-cover" transactions to satisfy tax withholding on vesting restricted stock units. The sales occurred at prices ranging from $10.14 to $10.50 and were not at her discretion. After these sales, she directly holds 35,770 shares, including 500 shares acquired under the company’s 2020 Employee Stock Purchase Plan.
Keros Therapeutics, Inc. (KROS) director Charles W. Newton reported selling 551 shares of common stock on August 18, 2026 in a transaction coded as an open market or private sale. The weighted average sale price was $10.30 per share, with individual trades between $10.16 and $10.49. After this sale, he directly holds 12,114 shares. The sale was made pursuant to a Rule 10b5-1 trading plan adopted on March 12, 2026.
Keros Therapeutics, Inc. (KROS) director Jean Jacques Bienaime reported an open-market purchase of common stock. On 2026-08-17, he purchased 1,000 shares at a weighted average price of $10.27 per share, executed in multiple trades between $10.02 and $10.39. Following this transaction, he directly holds 19,592 shares of Keros Therapeutics common stock. The purchase was made pursuant to a Rule 10b5-1 trading plan adopted on December 5, 2025.
Keros Therapeutics director Jean Jacques Bienaime purchased 1,000 shares of Common Stock on July 15, 2026 at a weighted-average price of $10.61 per share, with individual trades between $10.46 and $10.80. The purchase was made under a Rule 10b5-1 trading plan adopted on December 5, 2025, increasing his direct holdings to 18,592 shares.
Keros Therapeutics director Anne Prener received new equity awards. On July 1, 2026, she was granted 13,786 shares of Common Stock as restricted stock units (RSUs), with no cash paid per share. These RSUs vest over three years in twelve equal quarterly installments starting August 15, 2026, if she remains in continuous service.
On the same date, she was also granted a stock option for 14,870 shares of Common Stock at an exercise price of $10.88 per share, expiring on June 30, 2036. This option vests in equal quarterly installments over three years beginning October 1, 2026, also conditioned on continued service. The filing shows no open-market buying or selling; these are compensation-related grants.
Keros Therapeutics director Jean Jacques Bienaime purchased 1,000 shares of common stock in an open‑market transaction at a weighted average price of $10.19 per share. After this buy, he directly holds 17,592 common shares. The purchase was made under a Rule 10b5-1 trading plan adopted on December 5, 2025, indicating it was pre‑scheduled rather than a discretionary trade.
Keros Therapeutics director Charles W. Newton reported an open-market sale of 550 shares of common stock at a weighted average price of $10.04 per share. The transaction occurred on June 11, 2026 and was executed under a pre-arranged Rule 10b5-1 trading plan adopted on March 12, 2026. After this sale, Newton directly holds 12,665 shares of Keros Therapeutics common stock.
Keros Therapeutics director Nima Farzan sold shares in a planned trade. On June 4, 2026, he sold 2,625 shares of Keros Therapeutics common stock in an open-market transaction at a weighted average price of $10.73 per share.
The sale was executed under a Rule 10b5-1 trading plan adopted on December 5, 2025, indicating it was pre-arranged. After these transactions, Farzan directly owns 9,767 shares of Keros Therapeutics common stock.
Keros Therapeutics director Julius Knowles reported an open-market sale of 2,625 shares of Common Stock at a weighted average price of $10.73 per share. The transaction was effected under a Rule 10b5-1 trading plan adopted on December 5, 2025.
Following the sale, Knowles holds 10,958 shares directly. In addition, 102,233 shares are held indirectly through Partners Innovation Fund, LLC and 150,047 shares are held indirectly through Partners Innovation Fund II, L.P., where entities associated with him may share voting and investment power.
Keros Therapeutics director Alpna Seth received equity-based compensation rather than buying shares on the market. On this Form 4, Seth was granted 7,142 restricted stock units of common stock and a stock option for 7,433 shares at an exercise price of $10.50 per share.
The RSUs vest in full on the earlier of June 3, 2027 or the company’s 2027 annual meeting of stockholders, as long as she continues providing service. The option vests in equal quarterly installments over 12 months following June 3, 2026, and will in any case be fully vested by the 2027 annual meeting, also subject to continued service. After these grants, she directly holds 12,392 common shares and 7,433 options.
Keros Therapeutics director Alpna Seth reported an open-market sale of 2,625 shares of common stock at a weighted average price of $10.72 per share on June 4, 2026. The shares were sold in multiple trades between $10.60 and $10.89. After this transaction, she directly holds 9,767 shares. The sale was made under a pre-arranged Rule 10b5-1 trading plan adopted on December 9, 2025, indicating the timing was planned in advance.
Keros Therapeutics director Mary Ann Gray received new equity awards. She was granted 7,142 shares of common stock in the form of restricted stock units that fully vest on the earlier of June 3, 2027 or the 2027 annual meeting, subject to continued service. She also received options for 7,433 shares at an exercise price of $10.50 per share, vesting in equal quarterly installments over 12 months after June 3, 2026 and fully vested by the 2027 annual meeting. Following the RSU grant, she directly holds 12,392 common shares.
Keros Therapeutics director Nima Farzan reported equity awards that increase his direct stake in the company. He received 7,142 shares of common stock through a restricted stock unit (RSU) grant, bringing his direct common stock holdings to 12,392 shares.
The RSUs fully vest on the earlier of June 3, 2027 or the company’s 2027 annual meeting of stockholders, if he continues to provide service. He was also granted a stock option for 7,433 shares at an exercise price of $10.50 per share, vesting in equal quarterly installments over the 12 months following June 3, 2026 and in any case fully vested by the 2027 annual meeting, subject to continued service. These are compensation-related awards rather than open-market purchases or sales.
Keros Therapeutics director Jean Jacques Bienaime reported equity awards rather than open-market trades. He received 7,142 shares of Common Stock as a restricted stock unit award, bringing his direct Common Stock holdings to 16,592 shares. The filing also shows a grant of options for 7,433 shares of Common Stock at an exercise price of $10.50 per share. The RSUs fully vest on the earlier of June 3, 2027 or the company’s 2027 annual meeting of stockholders, while the options vest in equal quarterly installments over 12 months following June 3, 2026 and in any case are fully vested by the 2027 annual meeting, in each case subject to continued service.
Keros Therapeutics director Julius Knowles reported new equity awards and updated his holdings. He received 7,142 restricted stock units that vest on the earlier of June 3, 2027 or the company’s 2027 annual meeting of stockholders, as long as he continues serving the company.
He also received a stock option covering 7,433 shares of common stock at an exercise price of $10.50 per share. This option vests in equal quarterly installments over the 12 months following June 3, 2026 and will in any case be fully vested by the 2027 annual meeting, subject to continued service. After these grants, he directly holds 13,583 common shares and also has indirect interests in 102,233 and 150,047 shares held by Partners Innovation Fund, LLC and Partners Innovation Fund II, L.P., where he may share voting and investment power.
Keros Therapeutics director Jean Jacques Bienaime bought 1,000 shares of common stock in an open-market transaction at a weighted average price of $10.58 per share. The trades on May 15, 2026 were executed under a Rule 10b5-1 trading plan adopted on December 5, 2025.
Following this purchase, he directly owns 9,450 Keros Therapeutics shares.
Keros Therapeutics director Jean Jacques Bienaimé made an open-market purchase of the company’s common stock. On April 15, 2026, he bought 1,000 shares at a weighted average price of $11.70 per share, increasing his direct holdings to 8,450 shares.
The shares were purchased under a Rule 10b5-1 trading plan that Bienaimé adopted on December 5, 2025. The filing notes the trade was executed through multiple transactions at prices between $11.56 and $11.80 per share.
Keros Therapeutics chief executive officer Jasbir Seehra exercised employee stock options to acquire 55,000 shares of common stock at an exercise price of $0.30 per share on April 2, 2026. These options were immediately exercisable. Following the transaction, he directly owned 440,708 shares of common stock.
Keros Therapeutics reported that Chief Legal Officer Esther Cho received a grant of employee stock options covering 80,000 shares of common stock. The options have an exercise price of $15.52 per share and expire on February 23, 2036. One quarter of the options vest on February 24, 2027, with the remaining shares vesting in twelve substantially equal quarterly installments, contingent on her continued service. This is a compensation-related award rather than an open‑market purchase.
Keros Therapeutics director Charles W. Newton received new equity awards. He was granted stock options covering 14,788 shares of Common Stock at an exercise price of $11.35 per share, expiring on March 8, 2036, and 13,215 restricted stock units.
The RSUs vest over three years in twelve equal quarterly installments starting on May 15, 2026, while the options vest over three years in equal quarterly installments starting on June 9, 2026, in each case subject to his continuous service. Following these awards, he directly holds 14,788 options and 13,215 shares.
Keros Therapeutics director Jean Jacques Bienaime bought 2,000 shares of common stock in an open-market transaction. The purchase took place on March 9, 2026 at a weighted average price of $11.21 per share, with individual trade prices ranging from $10.98 to $11.48. Following this transaction, Bienaime directly owns 7,450 Keros shares. The filing notes that the trade was executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 5, 2025, indicating the purchase was scheduled in advance rather than timed discretionarily.
Keros Therapeutics reported that Chief Executive Officer Jasbir Seehra received grants of employee stock options covering a total of 317,000 shares of common stock. One grant for 217,000 options vests over time, with one-fourth vesting on February 24, 2027 and the remainder in twelve equal quarterly installments thereafter, contingent on continued service.
The second grant for 100,000 options vests in four equal tranches based on stock price performance. Each one-fourth vests if the company’s share price closes at or above 125%, 150%, 175% and 200% of the exercise price, respectively, for 30 calendar days between February 24, 2026 and February 24, 2031, subject to Seehra’s continuous service. These are option awards, not open-market stock purchases or sales.
Regnante Keith reported acquisition or exercise transactions in this Form 4 filing.
Keros Therapeutics reported that its Chief Financial Officer, Keith Regnante, received a grant of stock options covering 60,000 shares of common stock. These options were awarded as an employee stock option grant at a stated price per share of $0.0000.
According to the terms, one-fourth of the options will vest on February 24, 2027, and the remaining options will vest in twelve substantially equal quarterly installments after that date, as long as he continues to provide service through each vesting date. After this award, he holds 60,000 derivative securities directly.
Cho Esther reported acquisition or exercise transactions in this Form 4 filing.
Keros Therapeutics Chief Legal Officer Esther Cho reported an equity award of employee stock options. On February 24, 2026, she was granted 80,000 options to buy Keros Therapeutics common stock, all held as direct ownership, bringing her total derivative holdings to 80,000 options.
According to the vesting terms, one-fourth of the shares subject to the option will vest on February 24, 2027. The remaining shares will then vest in twelve substantially equal quarterly installments, as long as she continues to provide service through each vesting date.
Lerner Lorena Raquel reported acquisition or exercise transactions in this Form 4 filing.
Keros Therapeutics Chief Scientific Officer Lorena Raquel Lerner received a grant of 75,000 employee stock options on February 24, 2026. These options were awarded at no cost as part of her compensation and increase her directly held derivative securities to 75,000.
One-fourth of the option grant will vest on February 24, 2027, with the remaining options vesting in twelve substantially equal quarterly installments after that date, so long as she continues to provide services to the company through each vesting date.
Keros Therapeutics chief executive officer Jasbir Seehra reported an open-market sale of 7,015 shares of common stock on February 19, 2026 at $16.17 per share. After this transaction, his directly held stake was 385,708 shares.
According to the disclosure, this was an automatic "sell-to-cover" transaction to satisfy tax withholding obligations triggered by the vesting of restricted stock units, and was not executed at his discretion.
Keros Therapeutics Chief Science Officer Lorena Raquel Lerner reported an automatic sale of 3,873 shares of common stock on February 18, 2026. The issuer has a “sell-to-cover” policy, so these shares were sold solely to cover tax withholding on vesting restricted stock units.
The open-market sale occurred at a weighted average price of $16.35 per share, with individual trades ranging from $16.05 to $16.65. After this tax-related transaction, Lerner directly held 31,127 shares of Keros Therapeutics common stock.
Keros Therapeutics SVP and General Counsel Esther Cho reported an automatic sale of 4,745 shares of common stock. The shares were sold in open-market transactions at a weighted average price of $16.35 per share, with individual trade prices ranging from $16.05 to $16.65.
According to the disclosure, Keros Therapeutics has a “sell-to-cover” policy for tax withholding, and these sales reflect shares sold to satisfy Ms. Cho’s tax obligations upon vesting of restricted stock units. The filing notes the sales were automatic and not at her discretion. After the transactions, she beneficially owned 39,755 shares, including 500 shares acquired under the company’s 2020 Employee Stock Purchase Plan.
Keros Therapeutics, Inc. chief financial officer Keith Regnante reported an automatic open-market sale of common stock tied to tax withholding on vested restricted stock units. He sold 4,739 shares on February 18, 2026 at a weighted average price of $16.35 per share, in multiple trades between $16.05 and $16.65. After these sell-to-cover transactions, he beneficially owns 39,261 shares of Keros Therapeutics common stock directly.
Keros Therapeutics CEO Jasbir Seehra reported a performance-based stock option update. On January 7, 2026, he was credited with 62,500 employee stock options with an exercise price of $63.61 per share, following certification of performance conditions by the board’s compensation committee.
The original grant, reported in February 2024, covered options for 125,000 shares subject to performance goals. The committee determined that targets tied to 62,500 shares were achieved, causing 31,250 shares to vest immediately and scheduling another 31,250 to vest on December 31, 2026, if he remains in continuous service through that date. Performance conditions tied to the remaining 62,500 shares were not met, and that portion of the option was forfeited for no consideration.
Keros Therapeutics, Inc. director-affiliated investment entities reported selling common stock in connection with the company’s completion of a cash tender offer. OrbiMed-related funds disposed of 140,057 shares and 74,465 shares of Keros common stock at a price of $17.75 per share on 11/21/2025. Following these transactions, one OrbiMed fund reported indirect beneficial ownership of 759,155 shares, and another reported 45,057 shares, while the reporting entities each disclaim beneficial ownership beyond their pecuniary interest.
Keros Therapeutics director Carl L. Gordon reported indirect sales of Keros Therapeutics, Inc. common stock in connection with the company’s completion of a cash tender offer. On 11/21/2025, 140,057 shares of common stock were disposed of at $17.75 per share, leaving 759,155 shares beneficially owned indirectly. On the same date, an additional 74,465 shares were disposed of at $17.75 per share, leaving 45,057 shares beneficially owned indirectly.
The shares are held through OrbiMed-affiliated investment entities, including OrbiMed Private Investments VII, LP and OrbiMed Genesis Master Fund, L.P. Various OrbiMed general partners and OrbiMed Advisors LLC may be deemed to share voting and investment power over these holdings, but each related entity and person, including the reporting person, disclaims beneficial ownership beyond any pecuniary interest.
Keros Therapeutics, Inc. director reported share dispositions tied to the company’s cash tender offer. On 11/21/2025, the reporting person tendered 191,527 shares of common stock at $17.75 per share and separately tendered 130,494 shares at $17.75 per share, as noted in footnote (1) describing an issuer cash tender offer that began on October 20, 2025 and whose final results were announced on November 20, 2025. Following these transactions, the director beneficially owns 150,047 shares indirectly through Partners Innovation Fund, LLC, 102,233 shares indirectly through Partners Innovation Fund II, L.P., and 6,441 shares directly.
Keros Therapeutics (KROS) — Form 4 filing: Pontifax-affiliated funds reported open market sales of common stock on 10/15/2025 at $17.75 per share. Reported disposals include 2,284,612 shares by Pontifax (Israel) IV, L.P.; 1,121,045 by Pontifax (Cayman) IV, L.P.; 1,226,412 by Pontifax (China) IV, L.P.; and 155,262 by Pontifax Late Stage Fund, L.P. Each fund reported 0 shares beneficially owned following the transactions.
The filing lists indirect ownership through Pontifax entities and indicates that Tomer Kariv and Ran Nussbaum each reported 5,250 shares indirectly. The footnotes state that, in connection with a Stock Purchase Agreement dated October 15, 2025 and their resignations from the board, the issuer accelerated the vesting of restricted stock units and certain options previously reported for Messrs. Kariv and Nussbaum.
Keros Therapeutics (KROS): Section 16 filing reports insider sales. On 10/15/2025, reporting persons linked to ADAR1 disclosed sales of Keros common stock at $17.75 per share. The transactions were reported as indirect holdings through affiliated entities.
Reported sales included 4,391,237 shares by ADAR1 Partners, LP; 254,669 shares by ADAR1 SPV I, LP; and 743,358 shares by Spearhead Insurance Solutions IDF, LLC. For each line item, the amount of securities beneficially owned following the transactions was listed as 0, with ownership form marked as indirect.
The filing notes that ADAR1 Capital Management, LLC (investment manager/sub‑advisor), ADAR1 Capital Management GP, LLC (general partner), and Daniel Schneeberger (manager) may be deemed to indirectly beneficially own the securities, and each disclaims beneficial ownership except to the extent of pecuniary interest.